Sec Form 4 Filing - Trainer John @ NexImmune, Inc. - 2023-04-04

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Trainer John
2. Issuer Name and Ticker or Trading Symbol
NexImmune, Inc. [ NEXI]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chief Financial Officer
(Last) (First) (Middle)
C/O NEXIMMUNE, INC., 9119 GAITHER ROAD
3. Date of Earliest Transaction (MM/DD/YY)
04/04/2023
(Street)
GAITHERSBURG, MD20877
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 0.41 04/04/2023 A 89,100 ( 1 ) 04/03/2033 Common Stock 89,100 $ 0 89,100 D
Stock Option (right to buy) $ 4.22 04/04/2023 D( 2 ) 78,100 ( 2 ) 04/04/2032 Common Stock 78,100 ( 2 ) 0 D
Stock Option (right to buy) $ 1.23 04/04/2023 A( 2 ) 27,660 ( 2 ) 04/04/2032 Common Stock 27,660 ( 2 ) 27,660 D
Stock Option (right to buy) $ 0.82 04/04/2023 A( 2 ) 50,440 ( 2 ) 04/04/2032 Common Stock 50,440 ( 2 ) 50,440 D
Stock Option (right to buy) $ 17 04/04/2023 D( 3 ) 28,987 ( 3 ) 02/10/2031 Common Stock 28,987 ( 3 ) 0 D
Stock Option (right to buy) $ 1.23 04/04/2023 A( 3 ) 18,720 ( 3 ) 02/10/2031 Common Stock 18,720 ( 3 ) 18,720 D
Stock Option (right to buy) $ 0.82 04/04/2023 A( 3 ) 10,267 ( 3 ) 02/10/2031 Common Stock 10,267 ( 3 ) 10,267 D
Stock Option (right to buy) $ 5.17 04/04/2023 D( 4 ) 102,949 ( 4 ) 03/04/2030 Common Stock 102,949 ( 4 ) 0 D
Stock Option (right to buy) $ 1.23 04/04/2023 A( 4 ) 89,222 ( 4 ) 03/04/2030 Common Stock 89,222 ( 4 ) 89,222 D
Stock Option (right to buy) $ 0.82 04/04/2023 A( 4 ) 13,727 ( 4 ) 03/04/2030 Common Stock 13,727 ( 4 ) 13,727 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Trainer John
C/O NEXIMMUNE, INC.
9119 GAITHER ROAD
GAITHERSBURG, MD20877
Chief Financial Officer
Signatures
/s/ John Rudy, attorney-in-fact 04/06/2023
Signature of Reporting Person Date
Explanation of Responses:
( 1 )25% of this option shall vest and become exercisable on April 4, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Trainer's continued service to the corporation on each vesting date.
( 2 )The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on April 5, 2022, of which 19,525 shares vested, and the remainder of the options will vest in equal monthly installments such that on April 5, 2026, all shares subject to the option shall be vested, subject to Mr. Trainer's continued service on each vesting date.
( 3 )The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which 28,987 shares vested, and the remainder of the options will vest in equal monthly installments such that on February 11, 2025, all shares subject to the option shall be vested, subject to Mr. Trainer's continued service on each vesting date.
( 4 )The reported transactions involved an amendment of an outstanding stock o ption grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which 130,401 shares vested, and the remainder of the options will vest in equal monthly installments such that on January 8, 2024, all shares subject to the option shall be vested, subject to Mr. Trainer's continued service on each vesting date. Mr. Trainer has exercised his right to purchase an aggregate of 61,769 shares subject to the original option.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.